drugset / Trial / NCT02857517
Intravitreal Conbercept for Idiopathic Choroidal Neovascularization
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy as primary treatment for ICNV.
Timeline
- Start
- 2016-06
- Primary completion
- 2018-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Conbercept | Protein / enzyme biologic | 0.05 ml | Intravitreal |